142 related articles for article (PubMed ID: 35964428)
1. Recent advances in combretastatin A-4 codrugs for cancer therapy.
Guo K; Ma X; Li J; Zhang C; Wu L
Eur J Med Chem; 2022 Nov; 241():114660. PubMed ID: 35964428
[TBL] [Abstract][Full Text] [Related]
2. A poly(l-glutamic acid)-combretastatin A4 conjugate for solid tumor therapy: Markedly improved therapeutic efficiency through its low tissue penetration in solid tumor.
Liu T; Zhang D; Song W; Tang Z; Zhu J; Ma Z; Wang X; Chen X; Tong T
Acta Biomater; 2017 Apr; 53():179-189. PubMed ID: 28167300
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.
Stevenson JP; Rosen M; Sun W; Gallagher M; Haller DG; Vaughn D; Giantonio B; Zimmer R; Petros WP; Stratford M; Chaplin D; Young SL; Schnall M; O'Dwyer PJ
J Clin Oncol; 2003 Dec; 21(23):4428-38. PubMed ID: 14645433
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, excretion, and distribution of combretastatin A4 phosphate in rats.
Xu XP; Wu XD; Liang GL; Huang WS; Wang L; Jing HY; Zhong SL
Pharmazie; 2012 Jun; 67(6):529-33. PubMed ID: 22822542
[TBL] [Abstract][Full Text] [Related]
5. Combretastatin A4 phosphate.
West CM; Price P
Anticancer Drugs; 2004 Mar; 15(3):179-87. PubMed ID: 15014350
[TBL] [Abstract][Full Text] [Related]
6. The codrug approach for facilitating drug delivery and bioactivity.
Aljuffali IA; Lin CF; Chen CH; Fang JY
Expert Opin Drug Deliv; 2016 Sep; 13(9):1311-25. PubMed ID: 27159251
[TBL] [Abstract][Full Text] [Related]
7. A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours.
He X; Li S; Huang H; Li Z; Chen L; Ye S; Huang J; Zhan J; Lin T
Br J Clin Pharmacol; 2011 Jun; 71(6):860-70. PubMed ID: 21276042
[TBL] [Abstract][Full Text] [Related]
8. Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate.
Kirwan IG; Loadman PM; Swaine DJ; Anthoney DA; Pettit GR; Lippert JW; Shnyder SD; Cooper PA; Bibby MC
Clin Cancer Res; 2004 Feb; 10(4):1446-53. PubMed ID: 14977848
[TBL] [Abstract][Full Text] [Related]
9. Combretastatin A4 phosphate: background and current clinical status.
Young SL; Chaplin DJ
Expert Opin Investig Drugs; 2004 Sep; 13(9):1171-82. PubMed ID: 15330748
[TBL] [Abstract][Full Text] [Related]
10. Dynamic bioluminescence and fluorescence imaging of the effects of the antivascular agent Combretastatin-A4P (CA4P) on brain tumor xenografts.
Liu L; Mason RP; Gimi B
Cancer Lett; 2015 Jan; 356(2 Pt B):462-9. PubMed ID: 25305449
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer.
Cooney MM; Radivoyevitch T; Dowlati A; Overmoyer B; Levitan N; Robertson K; Levine SL; DeCaro K; Buchter C; Taylor A; Stambler BS; Remick SC
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):96-100. PubMed ID: 14734457
[TBL] [Abstract][Full Text] [Related]
12. Peripherally cross-linking the shell of core-shell polymer micelles decreases premature release of physically loaded combretastatin A4 in whole blood and increases its mean residence time and subsequent potency against primary murine breast tumors after IV administration.
Wakaskar RR; Bathena SP; Tallapaka SB; Ambardekar VV; Gautam N; Thakare R; Simet SM; Curran SM; Singh RK; Dong Y; Vetro JA
Pharm Res; 2015 Mar; 32(3):1028-44. PubMed ID: 25223962
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, in vitro, and in vivo evaluation of phosphate ester derivatives of combretastatin A-4.
Hadimani MB; Hua J; Jonklaas MD; Kessler RJ; Sheng Y; Olivares A; Tanpure RP; Weiser A; Zhang J; Edvardsen K; Kane RR; Pinney KG
Bioorg Med Chem Lett; 2003 May; 13(9):1505-8. PubMed ID: 12699742
[TBL] [Abstract][Full Text] [Related]
14. Review of Cytotoxic CA4 Analogues that Do Not Target Microtubules: Implications for CA4 Development.
Tarade D; Pandey S; McNulty J
Mini Rev Med Chem; 2017; 17(16):1507-1514. PubMed ID: 27156516
[TBL] [Abstract][Full Text] [Related]
15. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P).
Siemann DW; Chaplin DJ; Walicke PA
Expert Opin Investig Drugs; 2009 Feb; 18(2):189-97. PubMed ID: 19236265
[TBL] [Abstract][Full Text] [Related]
16. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.
Dowlati A; Robertson K; Cooney M; Petros WP; Stratford M; Jesberger J; Rafie N; Overmoyer B; Makkar V; Stambler B; Taylor A; Waas J; Lewin JS; McCrae KR; Remick SC
Cancer Res; 2002 Jun; 62(12):3408-16. PubMed ID: 12067983
[TBL] [Abstract][Full Text] [Related]
17. Targeted polymeric micelle system for delivery of combretastatin A4 to tumor vasculature in vitro.
Wang Y; Yang T; Wang X; Wang J; Zhang X; Zhang Q
Pharm Res; 2010 Sep; 27(9):1861-8. PubMed ID: 20559700
[TBL] [Abstract][Full Text] [Related]
18. A single dose of intravenous combretastatin A4-phosphate is reasonably well tolerated and significantly reduces tumour vascularization in canine spontaneous cancers.
Abma E; De Spiegelaere W; Vanderperren K; Stock E; Van Brantegem L; Cornelis I; Daminet S; Ni Y; Vynck M; Verstraete G; Smets P; de Rooster H
Vet Comp Oncol; 2018 Dec; 16(4):467-477. PubMed ID: 29797763
[TBL] [Abstract][Full Text] [Related]
19. Combretastatin A4 phosphate: a novel vascular disrupting agent.
Nagaiah G; Remick SC
Future Oncol; 2010 Aug; 6(8):1219-28. PubMed ID: 20799867
[TBL] [Abstract][Full Text] [Related]
20. Combretastatin A4-induced differential cytotoxicity and reduced metastatic ability by inhibition of AKT function in human gastric cancer cells.
Lin HL; Chiou SH; Wu CW; Lin WB; Chen LH; Yang YP; Tsai ML; Uen YH; Liou JP; Chi CW
J Pharmacol Exp Ther; 2007 Oct; 323(1):365-73. PubMed ID: 17646428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
